VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

11024	Companies
241652	Keywords
170126	Articles
130102	Press releases

Home
Companies
VALNEVA

PRESS RELEASE

published on 01/09/2026 at 07:00, 8 months 9 days ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Valneva SE to meet with investors at the J.P. Morgan Healthcare Conference to discuss upcoming catalysts from its clinical development pipeline and commercial portfolio of vaccines. Company specializes in prophylactic vaccines for infectious diseases

Valneva SE Prophylactic Vaccines J.P. Morgan Healthcare Conference Vaccine Company Clinical Development Pipeline
BRIEF

published on 12/31/2025 at 17:50, 8 months 18 days ago

Valneva and Serum Institute End Chikungunya Vaccine Collaboration

Public Health Valneva License Agreement Chikungunya Vaccine Serum Institute
PRESS RELEASE

published on 12/31/2025 at 17:45, 8 months 18 days ago

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Valneva and Serum Institute of India mutually agree to discontinue chikungunya vaccine license. Valneva aims for direct control over supply chain and access to high-risk regions

Valneva License Agreement CEPI Chikungunya Vaccine Serum Institute Of India
BRIEF

published on 12/10/2025 at 17:50, 9 months 8 days ago

Valneva obtains positive results in Phase 2 for the chikungunya vaccine in children

Valneva Safety Vaccine Phase 2 Chikungunya
BRIEF

published on 12/10/2025 at 17:50, 9 months 8 days ago

Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children

Valneva SE Phase 2 Study Children's Health Chikungunya Vaccine Vaccine Safety
PRESS RELEASE

published on 12/10/2025 at 17:45, 9 months 8 days ago

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
Valneva reports positive final phase 2 antibody persistence and safety results for children with its Chikungunya vaccine IXCHIQ®. Twelve-month data supports full dose selection for Phase 3 trial

Phase 3 Trial Valneva Vaccine Chikungunya Antibody Persistence
BRIEF

published on 12/05/2025 at 18:39, 9 months 13 days ago

Valneva Updates Share and Voting Rights as of November 2025

Stock Options Euronext Paris Voting Rights Valneva Double Voting Rights
BRIEF

published on 12/05/2025 at 18:39, 9 months 13 days ago

VALNEVA: Declaration of Shares and Voting Rights

Euronext Paris Voting Rights Ordinary Shares Valneva 2025
PRESS RELEASE

published on 12/05/2025 at 18:34, 9 months 13 days ago

VALNEVA Declaration of shares and voting rights: November 30, 2025
VALNEVA declares changes in shares and voting rights, including double voting rights granted on ordinary shares and transfer into bearer form

Euronext Paris Voting Rights Shares Valneva Double Voting Rights
BRIEF

published on 12/03/2025 at 11:03, 9 months 15 days ago

Valneva SE: Promising Developments in Lyme Disease Vaccine

Valneva SE Lyme Disease Vaccine Market Forecast Pfizer VLA15

Accesswire

Published on 09/18/2026 at 22:00, 1 hour 26 minutes ago

Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 2 hours 51 minutes ago

Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 8 hours 56 minutes ago

AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/18/2026 at 13:30, 9 hours 56 minutes ago

Alset AI Provides Shareholder Update, Announces Updated Investor Presentation and Appoints Mitchell Jackman as Chief Financial Officer
Published on 09/18/2026 at 06:30, 16 hours 56 minutes ago

GREE Chairperson Dong Mingzhu Honored by UNEP Cool Coalition for Leadership in Sustainable Cooling

View all ACCESSWIRE

EQS Group

Published on 09/18/2026 at 18:45, 4 hours 41 minutes ago

Holding(s) in Company
Published on 09/18/2026 at 18:44, 4 hours 41 minutes ago

EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:13, 5 hours 13 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:09, 5 hours 16 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS
Published on 09/18/2026 at 18:07, 5 hours 19 minutes ago

Multi Units Luxembourg: NOTICE TO SHAREHOLDERS

Les Echos

Published on 09/18/2026 at 18:34, 4 hours 51 minutes ago

Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 17:45, 5 hours 41 minutes ago

Press Release_Carrefour Bond_September 2026
Published on 09/18/2026 at 17:45, 5 hours 41 minutes ago

Share buyback for cancellation
Published on 09/17/2026 at 17:40, 1 day 5 hours ago

Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 20:46, 2 days 2 hours ago

LNA SANTE : 2026 First Half Results

View all LES ECHOS COMFI WIRE